Home » Stocks » Silence Therapeutics

Silence Therapeutics PLC (SLN)

Stock Price: $15.50 USD 0.00 (0.00%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.28B
Revenue (ttm) 244,000
Net Income (ttm) -19.58M
Shares Out 82.83M
EPS (ttm) -0.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $15.50
Previous Close $15.50
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 15.28 - 15.50
Day's Volume 0
52-Week Range 15.28 - 20.50

More Stats

Market Cap 1.28B
Enterprise Value 1.25B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 82.83M
Float n/a
EPS (basic) -0.78
EPS (diluted) -0.78
FCF / Share 0.07
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 0.13%
Payout Ratio n/a
Shares Short 948
Short Ratio 0.70
Short % of Float n/a
Beta 0.93
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 747.27
PS Ratio 5,261.50
PB Ratio 11.81
Revenue 244,000
Operating Income -22.73M
Net Income -19.58M
Free Cash Flow 1.72M
Net Cash 33.80M
Net Cash / Share 0.41
Gross Margin 100.00%
Operating Margin -9,317.21%
Profit Margin -8,025.40%
FCF Margin 704.10%
ROA -26.15%
ROE -81.78%
ROIC 85.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit0.24-
Operating Income-22.73-20.57
Net Income-19.58-18.41
Shares Outstanding78.37-
Earnings Per Share-0.78-0.78
Operating Cash Flow1.73-16.76
Capital Expenditures-0.01-0.13
Free Cash Flow1.72-16.89
Cash & Equivalents33.5226.54
Total Debt-0.29-
Net Cash / Debt33.8026.54
Book Value20.9135.06
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Silence Therapeutics PLC
Country United Kingdom
Employees 46
CEO Mark A. Rothera

Stock Information

Ticker Symbol SLN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SLN


Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.